Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
VG2062 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2062, and recommended dose of VG2062 for Phase II trials.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-21.
Status change: Not Yet Recruiting → Recruiting 2026-03-22
Trial Details
NCT Number NCT07262164
Lead Sponsor Shanghai Virogin Biotech Co., Ltd.
Conditions Advanced Malignant Solid Tumor
Enrollment 30 participants
Start Date 2026-03-18
Primary Completion 2027-05 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-25